semaglutide pulled from market An Ongoing Crisis: Shortage Raises Dual Concerns for Obesity and Diabetes Treatment FDA alerts health care providers,

Beginning around 2019, incidence curves for overall NSHL began to diverge, with GLP-1RA users showing consistently higher rates by 2023-2024

In other words, the claim is not that everyone will be harmed, but that a subset of patients who suffered severe and persistent symptoms may have experienced an abnormal or prolonged effect on digestion and intestinal movement

For younger patients considering GLP-1 treatment, this genetic insight can support more informed conversations with healthcare providers about whether such therapy aligns with individual risk-benefit profiles

doi: 10.1177/87551225241289959

Additionally, growth hormone influences cell turnover and apoptosis, contributing to healthier and more youthful-looking skin (1)